Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Progenra's ubiquitin carboxyl-terminal hydrolase inhibitors show preclinical antitumor activity

April 8, 2011

Progen Pharma completes enrollment in phase I trial of PG-11047

April 6, 2011

Phase II PX-866 trial in glioblastoma begins enrollment

April 6, 2011

New androgen receptor ligands described by Bayer Schering Pharma

April 6, 2011

Navitoclax enhances efficacy of taxanes in models of NSCLC

April 6, 2011

RRx-001 to enter clinic as chemotherapeutic/radiosensitizer for cancer

April 6, 2011

New PTEN/TP53/RB1 triple knockout model described of high-grade astrocytoma

April 6, 2011

MK-2206 advances to phase II testing in breast cancer

April 6, 2011

Morphotek acquires tumor-targeting peptide platform from TransMolecular

April 5, 2011

Pan-Akt inhibitor GDC-0068 demonstrates in vivo antitumor effects

April 5, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...